DaVita Appoints Jessica Hergenreter as Chief People Officer
Get Alerts DVA Hot Sheet
Join SI Premium – FREE
In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek.
"Our incredible teammates are the difference makers for the care we provide to patients," said
Before joining DaVita, Hergenreter spent 13 years at Vail Resorts, where she excelled in various leadership roles, from HR business partner to Chief of Staff to the CEO. Most recently, she led talent strategies that shaped the experience for 55,000 Vail Resorts employees, focusing on talent acquisition, development, and fostering a culture of diversity and inclusion. Earlier in her career, she provided HR consulting for a diverse range of clients, honing her expertise across industries.
"Having lived and worked in
To learn more about DaVita and its leadership, visit DaVita.com/About.
About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of
Media Contacts:
DaVita Newsroom
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-appoints-jessica-hergenreter-as-chief-people-officer-302279544.html
SOURCE DaVita
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Insurance Agent Nick Hogan Explains What First-Time Homeowners Often Miss About Homeowners Insurance in HelloNation
- Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC
- Bruckner Named Managing Partner After Four Years Leading M&A Practice
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share